Associations between the use of aspirin or other antiplatelet drugs and all-cause mortality among patients with COVID-19: A meta-analysis
Open Access
- 5 October 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 989903
Abstract
Introduction: Whether aspirin or other antiplatelet drugs can reduce mortality among patients with coronavirus disease (COVID-19) remains controversial.Methods: We identified randomized controlled trials, prospective cohort studies, and retrospective studies on associations between aspirin or other antiplatelet drug use and all-cause mortality among patients with COVID-19 in the PubMed database between March 2019 and September 2021. Newcastle–Ottawa Scale and Cochrane Risk of Bias Assessment Tool were used to assess the risk of bias. The I2 statistic was used to assess inconsistency among trial results. The summary risk ratio (RR) and odds ratio (OR) were obtained through the meta-analysis.Results: The 34 included studies comprised three randomized controlled trials, 27 retrospective studies, and 4 prospective cohort studies. The retrospective and prospective cohort studies showed low-to-moderate risks of bias per the Newcastle–Ottawa Scale score, while the randomized controlled trials showed low-to-high risks of bias per the Cochrane Risk of Bias Assessment Tool. The randomized controlled trials showed no significant effect of aspirin use on all-cause mortality in patients with COVID-19 {risk ratio (RR), 0.96 [95% confidence interval (CI) 0.90–1.03]}. In retrospective studies, aspirin reduced all-cause mortality in patients with COVID-19 by 20% [odds ratio (OR), 0.80 (95% CI 0.70–0.93)], while other antiplatelet drugs had no significant effects. In prospective cohort studies, aspirin decreased all-cause mortality in patients with COVID-19 by 15% [OR, 0.85 (95% CI 0.80–0.90)].Conclusion: The administration of aspirin may reduce all-cause mortality in patients with COVID-19.Keywords
Funding Information
- National Natural Science Foundation of China (82173499)
- Liaoning Revitalization Talents Program (XLYC2007001)
This publication has 84 references indexed in Scilit:
- The preventive effect of antiplatelet therapy in acute respiratory distress syndrome: a meta-analysisCritical Care, 2018
- Focal Cerebral ArteriopathyStroke, 2017
- Antiviral activity of aspirin against RNA viruses of the respiratory tract—an in vitro studyInfluenza and Other Respiratory Viruses, 2016
- Aspirin as a potential treatment in sepsis or acute respiratory distress syndromeCritical Care, 2015
- Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatmentsThe Lancet, 2015
- Aspirin and immune systemInternational Immunopharmacology, 2012
- The mechanism of action of aspirinThrombosis Research, 2003
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Modes of action of aspirin-like drugs: Salicylates inhibit Erk activation and integrin-dependent neutrophil adhesionProceedings of the National Academy of Sciences, 1998
- Aspirin and Platelets: The Antiplatelet Action of Aspirin and Its Role in Thrombosis Treatment and ProphylaxisSeminars in Thrombosis and Hemostasis, 1997